VRK1 and neoplasm: Thus, it is a starting point for the development of better inhibitors targeting VRK1, which can be used in combination with additional inhibitors directed to proteins in other signaling pathways, and which in cooperation can facilitate tumor cell death at lower drug doses in synthetic lethality strategies [39].